Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims (dose form/route, 500 mg regimen schedule, general HR+/postmenopausal advanced/metastatic use after endocrine therapy, and injection-site reactions) are supported or not contradicted by the provided excerpts. However, the AI-generated content includes several mechanistic/wording claims and side effect claims (e.g., hot flushes, nausea, fatigue, musculoskeletal pain; 'selective estrogen receptor degrader') that are not explicitly supported in the supplied label text, plus an overbroad claim about using in men 'in some indications' not supported by the provided excerpts.
Category Scores
Accurate Statements
“Fulvestrant 500 mg” refers to an injection of fulvestrant at a dose of 500 milligrams.
Dose/route for FASLODEX 500 mg: Section 2.1 and dosage forms/strength context Section 3.
Fulvestrant is used to treat hormone-receptor positive breast cancer in postmenopausal women.
Section 1 INDICATIONS AND USAGE (HR-positive advanced breast cancer in postmenopausal women).
Fulvestrant is used to treat advanced (metastatic) or hormone-receptor positive breast cancer when the cancer has progressed after prior endocrine therapy.
Section 1 INDICATIONS AND USAGE (disease progression following endocrine therapy; HR-positive advanced breast cancer in postmenopausal women).
Fulvestrant dosing for 500 mg is typically given as intramuscular injections.
Section 2.1 (intramuscularly into the buttocks).
The 500 mg fulvestrant dose is commonly delivered in multiple injections per dose.
Section 2.1 (two 5 mL injections, one in each buttock).
The 500 mg fulvestrant dose is commonly given as two injections to reach the full 500 mg.
Section 2.1 (two 5 mL injections; FASLODEX 500 mg administered as two 5 mL injections total).
A common schedule for fulvestrant 500 mg is monthly maintenance dosing after an initial loading phase.
Section 2.1 (Days 1, 15, 29, and once monthly thereafter).
Common side effects of fulvestrant can include injection-site reactions.
Section 6.1 (Injection site pain and other adverse reactions reported across clinical trials).
Fulvestrant may require extra monitoring in people with liver issues.
Hepatic impairment increased exposure and dose modification guidance: Section 2.2 and Warnings/Precautions 5.2; also Use in Specific Populations 8.6.
Unsupported Statements
Fulvestrant is an anti-estrogen medicine.
Mechanism in provided label excerpt is 'estrogen receptor antagonist' (Section 12.1) but the specific phrasing 'anti-estrogen' is not explicitly stated.
Fulvestrant is a selective estrogen receptor degrader.
The provided mechanism excerpt (Section 12.1) describes ER antagonist and downregulation, but the specific term 'selective estrogen receptor degrader' is not explicitly stated in the supplied excerpts.
Fulvestrant is used to treat certain types of breast cancer that are hormone-receptor positive.
This is broadly consistent with Section 1, but the statement is overly general and does not specify the HR-positive advanced/metastatic context shown; the provided excerpts include HR-positive advanced breast cancer, not all HR-positive breast cancer.
Fulvestrant is used to treat hormone-receptor positive breast cancer in men in some indications.
The provided indication excerpts specify postmenopausal women; no male indication language is included in the supplied label text.
Common side effects of fulvestrant can include hot flushes.
Hot flushes are not listed in the provided adverse reaction excerpts.
Common side effects of fulvestrant can include fatigue.
Fatigue is not listed in the provided adverse reaction excerpts.
Common side effects of fulvestrant can include nausea.
Nausea is not listed in the provided adverse reaction excerpts.
Common side effects of fulvestrant can include musculoskeletal pain.
Myalgia is mentioned in postmarketing adverse reactions for the 250 mg presentation (Section 6.2), but 'musculoskeletal pain' and 'common side effects' wording are not explicitly stated in the provided excerpts.
Fulvestrant may require extra monitoring in patients where the treatment may interact with other medicines.
The provided drug interaction section states there are no known drug-drug interactions and no dose adjustment is needed (Section 7). The claim implies clinically relevant interaction monitoring, which is not supported by the provided text.
There are other presentation strengths and some regions use different dosing schedules for fulvestrant.
The provided excerpts only show FASLODEX supplied as 250 mg/5 mL prefilled syringes for IM administration and dosing schedule for 500 mg; no label support is provided for 'other presentation strengths' beyond the 250 mg vs 500 mg comparison in clinical studies, nor for 'different dosing schedules in some regions.'
Fulvestrant 500 mg is the same drug (fulvestrant) but at the 500 mg regimen.
While consistent conceptually, the statement is not explicitly stated in the provided label excerpts as written.
Contradictions
Low
AI Statement
Fulvestrant is a selective estrogen receptor degrader.
Label Reference
Section 12.1
Important Omissions
Specific boxed warning/contraindication details were not addressed in the AI claims provided (e.g., hypersensitivity contraindication; embryo-fetal toxicity contraception/lactation guidance; bleeding risk; sciatic nerve/dorsogluteal caution).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Core dosing/route and general indication alignment are largely correct. Potential patient risk is mainly from unsupported/overbroad claims (male indications; interaction monitoring phrasing) and incomplete safety/administration warnings not reflected in the provided AI statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several statements are not explicitly supported by the provided prescribing information excerpts (e.g., SERD phrasing, specific side effects like hot flushes/nausea/fatigue, male indications, and drug-interaction monitoring).
Suggested Improvement
Limit mechanistic and adverse reaction wording to claims explicitly present in the provided label excerpts (e.g., describe fulvestrant as an estrogen receptor antagonist that downregulates ER per Section 12.1; specify adverse reactions only as listed such as injection-site pain and postmarketing items in Section 6.2; do not infer male indications or interaction monitoring not stated in Section 7).